GSK keeps guidance as specialty drugs power sales, but £328m restructuring charge dents profit

GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

GSK Q3 preview: Analysts project solid quarter, cost-saving progress in focus (GSK:NYSE)

GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

Gilead to Report Q3 Earnings: How Should You Play the Stock Now?

GSK to double down in oncology (GSK:NYSE)

What Could GSK (LSE:GSK) Oncology Progress Mean For Investors?

Amgen: A Biotech Bargain Heading Into Q3 Earnings

Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4

GSK Stock Technicals: Gains 1.11% on Monday, Testing Key Resistance

GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma

Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

GSK plc (GSK) Stock Forecasts